January 23 – 27, 2015 • San Diego, CA
Tuesday January 26th 12.30 – 1.45pm
“Interrogating Ligand: Target Interactions using Back-Scattering Interferometry Yields Mechanistic Insights and Aids in Compound Prioritization”
Presented by Layton Harris Smith, PhD, Director, Drug Discovery – Florida, Sanford Burnham Prebys Medical Discovery Institute
Integral membrane proteins such as GPCRs are critical targets for drug discovery but present a host of challenges to the characterization of their binding affinities for small molecules. Determination of allosteric binding in GPCR targets is especially valuable and extremely challenging information to obtain by established binding assay platforms, but can be addressed through a label-free solution-based direct-binding technology, back-scattering interferometry (BSI).
VIB Conference – Next-Generation Antibodies and Protein Analysis: Tools and Technologies
June 15-16, 2015 • Gent, Belgium
Discovery on Target 2015
September 21-24, 2015 • Boston, MA
Seminar: Wednesday, September 23 at 4:35pm during the track on EMERGING STRATEGIES FOR KINASE INHIBITOR DISCOVERY
Binding Studies of Type I, Type II and Type III Kinase Inhibitors against Bcr-Abl Kinase using TruBind™ Back-Scattering Interferometry presented by Scot Weinberger, Executive Vice President, Research and Development, Molecular Sensing, Inc.
Abnormal kinase activity contributes to the onset of cancer. Most kinase inhibitors are Type I inhibitors that bind to the ATP binding site or Type II that bind partially to the ATP site. TruBind(tm) technology studied the interaction of Type I, II, and III (allosteric) inhibitors of Bcr-Abl kinase. Binding studies of class I, II, and III inhibitors confirmed target engagement and provided inhibitor affinity assessment.
2nd Annual Drug Discovery USA Congress
October 29-30, 2015 • Boston, MA
World Pre-Clinical Congress: Targeting GPCR’s
June 10-12, 2015 • Boston, MA
Seminar: “A label-free, solution-based affinity assay for allosteric GPCR ligand binding using Back-Scattering Interferometry” presented by Richard J. Isaacs, PhD, Molecular Sensing, Inc. The presentation will occur during the Targeting GPCR’s track on Wednesday, June 10 from 3:35 – 4:05pm.
2nd NovAliX Conference – Biophysics in Drug Discovery 2015
June 9 – June 12, 2015 • Strasbourg, France
16th Annual Drug Discovery Summit 2015
June 8-9, 2015 • Berlin, Germany
Seminar: TruBind™ BSI Analysis Facilitates Target – Small Molecule Binding Research in CNS, GPCR, Kinase, and Allosteric Studies
TruBind BSI technology uniquely provides free-solution, label-free, and conformation sensitive detection of target engagement and Kd determination for small molecule drug candidates. This presentation opens with a brief description of TruBind technology and then proceeds to review its application in the analysis of CNS aggregate – storage disease (Alzheimer’s, Lewy Body); Class A, B, and C GPCR targets; and type I, II, and III inhibitors of Bcr-Abl kinase. A particular focus upon allosteric studies will be presented. The presentation will occur during the Target Based Discovery stream on Monday, June 8th at 11:30am-12pm.
Drug Discovery Chemistry 2015
April 21-23, 2015 • San Diego, CA
Seminar: “Binding studies of Type I, II and III kinase inhibitors against Bcr-Abl kinase using Back-Scattering Interferometry” presented by Scot R. Weinberger, EVP Molecular Sensing, Inc. The presentation will occur during the Kinase Inhibitor Chemistry track on Wednesday, April 22 from 3:10 – 3:40pm.
February 7-11, 2015 • Washington, DC
Exhibitor Tutorial: Tuesday, February 10th from 2 – 2:45pm in room 143c.
Conformation-Sensitive Assay Detection for Accelerated Drug Discovery Research
Learn about the superior analytical power of TruBind™ Back Scattering Interferometry (BSI) technology for molecular interaction studies.
TruBind BSI technology offers significant advantages over conventional methods by providing direct binding Kd determinations and confirming target engagement by leveraging label-free, conformation-sensitive detection. Designed to analyze complex and intractable drug targets maintained in native or native-like environments, this technology platform is ideal for studying allosteric kinases and GPCR’s as membrane preps, solubilized proteins, nanodiscs or amphipols, Ion Channels, RTK’s, Allosteric Contractile Proteins, Tau and Alpha Synuclein Fibrils, Transcription Factors, and Transporter Proteins.
Molecular Sensing’s tutorial begins with a brief review of the science and technology fundamentals and then proceeds to a detailed discussion of the direct application of TruBind BSI technology to a variety of challenging targets. Come learn about TruBind Assay Services and the TruBind 100 System to see how BSI technology can accelerate your drug discovery research.
ELRIG: Drug Discovery 2014
Manchester, UK • September 2-3, 2014
Booth # F6
Feature: Introduction of the TruBind™ BSI System and Assay Services
Poster presentation: Novel GPR39 Agonists: Correlation of binding affinity using label-free Back Scattering Interferometry with potency in functional assays.
The use of Backscattering Interferometry to Investigate Positive Allosteric Modulators of the M4 Receptor
3-September-2014, at 15:00
Presented by Dr. Jon Ellery, Principal Scientist, Takeda Cambridge, Ltd.
Basel, Switzerland • September 23-25, 2014
Booth # A52
Features: Introduction of the TruBind™ BSI System and Assay Services
Poster presentation: Yes. Title forthcoming
Back-Scattering Interferometry: A New Era In Label-Free, Conformation Sensitive Molecular Interaction Assay Technology for Drug discovery
25th September, 12:30 – 13:30
Presented by Scot Weinberger, Co-founder of MSI, EVP of R&D
The MSI MipTech Industry Symposium will present the enabling analytical power of Back-Scattering Interferometry (BSI) as applied to molecular interaction studies in drug discovery research. BSI provides direct binding Kd determinations with label-free, conformation-sensitive detection. BSI delivers significant advantages over conventional methods for complex and intractable drug targets maintained in native or native-like environments, including: allosteric kinases and GPCR’s as membrane preps, solubilized proteins, nanodiscs or amphipols; Ion Channels; RTK’s; Allosteric Contractile Proteins; Tau and Alpha Synuclein Fibrils; Transcription Factors; and Transporter Proteins.
The Symposium begins with a review of BSI theory and fundamentals and then proceeds to discuss the direct application of BSI technology to a variety of challenging targets including: GPCR’s, contractile proteins, kinases, and fibrils. Molecular Sensing will introduce its TruBind™ Assay Services and TruBind 100 automated BSI system. An interactive question and answer format will be utilized throughout the course of the symposium.